Drug Profile
Research programme: RNAi therapeutics - GeneCare
Alternative Names: RNAi therapeutics research programme - GeneCareLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GeneCare Research Institute
- Class Gene therapies
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
- 11 Jan 2005 Preclinical trials in Cancer in Japan (unspecified route)